Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib After Autologous Stem Cell Transplantation in Double-Hit B-Cell Lymphoma
NCT02272686Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in double hit B-cell lymphoma (DHL), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2016; status: terminated.
02
Drugs
ibrutinib
03
Conditions
double hit B-cell lymphoma (DHL)
Beyond the preview
Go deeper on NCT02272686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02272686.